Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
In this study, we aim to broaden our understanding of IBTK’s function in B-lymphoma, with a particular focus on its impact on the expression of the oncogene MYC. Here, we assessed the effects of combining Rituximab with IBTK silencing on cell viability through cell cycle analysis and Annexin V assays in vitro. Furthermore, we leveraged the transplantability of Eμ-myc lymphomas to investigate whether the inhibition of IBTK could elicit anti-tumor effects in the treatment of lymphomas in vivo. Our data suggests that IBTK silencing may serve as an effective anti-tumor agent for aggressive B-Lymphomas, underscoring its role...
Source: Frontiers in Oncology - February 2, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 649: Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins & rsquo;s Lymphoma Patients & mdash;A Single Centre Experience
Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised. (Source: Cancers)
Source: Cancers - February 2, 2024 Category: Cancer & Oncology Authors: Lea Galunic Bilic Fedor Santek Zdravko Mitrovic Sandra Basic-Kinda Dino Dujmovic Marijo Vodanovic Inga Mandac Smoljanovic Slobodanka Ostojic Kolonic Ruzica Galunic Cicak Igor Aurer Tags: Article Source Type: research
Gemcitabine ‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes
ConclusionsThe GBM/GBC regimen is effective and well-tolerated, offering outcomes that are highly comparable to those in NHL patients conditioned with BEAM/BEAC, as demonstrated in a prognostically matched cohort. (Source: Cancer Medicine)
Source: Cancer Medicine - February 1, 2024 Category: Cancer & Oncology Authors: Huimin Liu,
Hesong Zou,
Dandan Shan,
Wei Liu,
Wenyang Huang,
Weiwei Sui,
Shuhui Deng,
Tingyu Wang,
Rui Lv,
Mingwei Fu,
Yan Xu,
Shuhua Yi,
Gang An,
Yaozhong Zhao,
Lugui Qiu,
Dehui Zou Tags: RESEARCH ARTICLE Source Type: research
Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma
CAR T-cell therapy toxicities, including CRS and immune cell-associated neurotoxicity syndrome (ICANS), can be significant and effective prophylactic strategies are needed. Duvelisib is an oral inhibitor of phosphoinositide 3-kinases (PI3K)- γ/δ and is FDA-approved therapy for CLL/NHL with an established safety profile. Pre-clinical work from our group has demonstrated that PI3K inhibition may prevent CRS.We are conducting a Phase I, 3 + 3 dose escalation and two-arm dose expansion, trial of duvelisib for CRS prophylaxis in patien ts (pts) undergoing standard-of-care (SoC) CAR T-cell therapy for non-Hodgkin lymphoma ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michael Slade, Michael P. Rettig, Zachary D Crees, Neha Mehta-Shah, Nancy L. Bartlett, Todd A Fehniger, Amanda Cashen, Dr. Iskra Pusic, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio, Armin Ghobadi Tags: 146 Source Type: research
Incidence of Restrictive Lung Disease Following Autologous Stem Cell Transplantation for High Risk Lymphoma
Serial monitoring of pulmonary function tests (PFT) following allogeneic hematopoietic cell transplants (HCT) is common, with both obstructive and restrictive lung defects well described. In contrast, serial monitoring of PFT post autologous HCT is less commonly performed, with the incidence of post-HCT lung disease ill-defined in this population. We now report the incidence of restrictive lung disease (RLD) in a series of autograft recipients undergoing transplantation for Hodgkin's (HL) or non-Hodgkin's lymphoma (NHL) at our center. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Matthew Whalen, Colin Hayes, Thomas Braun, Dawson Myers, John Magenau, John Maciejewski, Sarah Anand, Mary Mansour Riwes, Ghada Abusin, Mark T. Vander Lugt, Monalisa Ghosh, Attaphol Pawarode, Sung Choi, Michael Triebwasser, Gregory A. Yanik Tags: 145 Source Type: research
Gaps in Long Term Follow up Assessment of Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant
Autologous hematopoietic stem cell transplantation (HSCT) offers an effective therapeutic strategy for patients with relapsed and refractory Hodgkin and non-Hodgkin lymphoma. Given their younger age, adolescent and young adult (AYA) patients typically present with fewer comorbidities at baseline. However, due to their relatively longer lifespan, they are more susceptible to late toxicities. It is commonly believed that after the challenges of lymphoma treatment, many young survivors aspire to lead a normal lifestyle, which, combined with the stresses of young adulthood, might decrease their compliance with follow-up. (Sour...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Yuliya Shestovska, Daniel Charles Stapor, Rashmi Khanal, Peter Abdelmessieh, Michael J Styler, Henry Fung, Asya Varshavsky Yanovsky Tags: 621 Source Type: research
Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
While checkpoint inhibition may theoretically improve T-cell effector function following CAR-T failure, a prospective trial of pembrolizumab following CAR-T in non-Hodgkin lymphoma (NHL) showed an ORR of only 25% (Chong Blood 2022). Nivolumab (nivo) has not been studied prospectively in this setting, and the efficacy of post-CAR-T checkpoint inhibition in multiple myeloma (MM) has not been characterized. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Rahul Banerjee, Ryan C Lynch, Qian Vicky Wu, Sylvain Simon, Chaitra S Ujjani, Brian G Till, Natalie Wuliji, Daria Gausman, Joshua Dizon, Mary L. Kwok, Sarah S. Lee, Rebecca W Silbermann, Eva Medvedova, David G. Maloney, Jorge Ramos, Mazyar Shadman, Jordan Tags: 549 Source Type: research
The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL: Real World Data from a Single Institution Experience
Non-Hodgkin lymphoma (NHL) in Saudi Arabia exhibits an incidence rate of 6.1%, with estimated age adjusted incidence is 6/100,000, presenting at an advanced stage up to 40% stage IV. The CD 19 chimeric antigen receptor (CAR) T-cell therapy targets and eliminates CD19-expressing B cells and shows efficacy against B-cell lymphomas. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Abdulrahman Nasiri, Alfadil Haroon Adam, Saud Alhayli, Naeem Chaudhri, Alfadel Alshaibani, Abdulwahab Albabtain, Hadeel Samarkandi, Ayman Saad, Abdullah Alamer, Tusneem A Elhassan, Hazzaa Alzahrani, Syed O Ahmed, Walid K. Rasheed, Riad El F Tags: 496 Source Type: research
Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.
Our study aimed to identify the impact of neighborhood disadvantage level on survival outcomes of recipients of CAR T-cell therapy as this has not yet been described. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Ronald M. Sobecks, Matt E. Kalaycio, Claudio G. Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, P Tags: 445 Source Type: research
